Methods for modifying electrical currents in neuronal circuits

• US 8,086,296 B2
• Filed: 08/27/2007
• Issued: 12/27/2011
• Est. Priority Date: 04/30/2002
• Status: Active Grant

• Current Assignee: BrainSonix Corporation
• Original Assignee: BrainSonix Corporation
• Inventors: Bystritsky, Alexander
• Primary Examiner(s): Casler, Brian
• Assistant Examiner(s): Cwern, Jonathan
• Application Number:
  US11/895,687
• Publication Number:
  US 20070299370A1
• Time in Patent Office: 1,583 Days
• Field of Search: 600/411, 600/427, 600/439, 601 2- 3
• US Class Current: 600/411
• CPC Class Codes: A61B 2090/374 NMR or MRI
• CPC Class Codes: A61N 2007/0078 with multiple treatment transducers
• CPC Class Codes: A61N 7/02 Localised ultrasound hyperthermia hyperthermia in general A61F7/00

Abstract

Disclosed herein are methods for modifying electrical currents in brain circuits through the simultaneous use of focused ultrasound pulse (FUP) and an existing brain-imaging system, such as a functional magnetic resonance imaging (fMRI) system. The methods are used for research, treatment and diagnosis of psychiatric, neurological, and neuroendocrine disorders whose biological mechanisms include brain circuits. The methods include the simultaneous steps of applying FUP to a live neuronal circuit within a brain and monitoring a brain image produced by a brain imaging system during the application of FUP.

Claims

1. A method of treating psychiatric, neurological and neuroendocrine disorders in a mammal, the method comprising the steps of:

applying a focused ultrasound pulse (FUP) to a live neuronal circuit in a tissue of the mammal, and the applied FUP uses a variation in pulsation parameter frequency to disrupt or activate a neuronal circuit function such that a naturally occurring hormone is released in the live neuronal circuit and in an organ connected to the live neuronal circuit and a level of the naturally occurring hormone is modulated; and

monitoring a tissue image including the live neuronal circuit from an imaging system during the application of the FUP.

2. The method of claim 1, wherein the mammal is a human.

3. The method of claim 1, wherein the tissue is a brain of the mammal.

4. The method of claim 1, wherein the imaging system is selected from the group consisting of a functional magnetic resonance image (fMRI) system;

a vector-electroencephalogram (V-EEG), and a positron emission tomograph (PET).

5. The method of claim 1, further comprising the step of:

administering a pharmaceutical medication to the mammal; and

assessing the tissue image from the imaging system after the administration of the pharmaceutical medication.

6. The method of claim 1, wherein the disruption or activation of the neurona circuit releases naturally occurring hormones in another neuronal circuit that is connected to the live neuronal circuit.

7. The method of cairn 1, wherein the disruption or activation of the neuronal circuit releases naturally occurring hormones in a gland that is connected to the live neuronal circuit.

8. A method of treating psychiatric, neurological and neuroendocrine disorders in a mammal, the method comprising the steps of:

applying a focused ultrasound pulse (FUP) to a tissue of a mammal, and the applied FUP uses a variation in frequency to disrupt or activate a tissue function such that a hormone level is modulated; and

monitoring a tissue image from an imaging system during the application of the FUP, wherein the tissue is a brain of the mammal and the FUP is applied to a live neuronal circuit within a brain region of the mammal, the brain region being selected from the group consisting of a hypothalamus and a medulla oblongata, and the applied FUP uses a low frequency to disrupt the neuronal circuits or a high frequency to activate the neuronal circuits, and wherein the brain image is monitored from the imaging system during the application of the FUP.

9. The method of claim 8, wherein the FUP is applied to the hypothalamus and the modulation is an increase or decrease in release of a hypothalamic hormone.

10. The method of claim 9, wherein the disorders are selected from the group consisting of sexual disorder, menstrual disorder, diabetes, growth disorder, blood pressure disorder, thyroid disorder, skin disorder, and wake sleep cycle disorder.

11. The method of claim 8, wherein the FUP is applied to a hypothalamic nuclei in the hypothalamus, the hypothalamic nuclei being selected from the group consisting of an anterior nuclei, a tuberal nuclei and a posterior nuclei.

12. The method of claim 8, wherein the hypothalamic hormone is selected from the group consisting of corticotrophin-releasing hormone, dopamine, gonadotropin-releasing hormone, growth hormone-releasing hormone, metonin, oxytocin, somatostatin, thyrotropin-releasing hormone, vasopressin, and mixtures thereof.

13. The method of claim 12, wherein the release of corticotrophin-releasing hormone is increased.

14. The method of claim 13, wherein the disorders are selected from the group consisting of rheumatoid arthritis, ulcerative colitis, lupus, and myelofibrosis.

15. The method of claim 12, wherein the release of corticotrophin-releasing hormone is decreased.

16. The method of claim 15, wherein the disorders are selected from the group consisting of cancer, opportunistic inflammations and fungal infections.

17. The method of claim 8, further comprising the step of:

applying at least one additional FUP to at least one other live neuronal circuit within the brain region.

18. The method of claim 8, wherein the FUP is applied to the medulla oblongata and the modulation is an effect on the sympathetic or parasympathetic nervous system.

19. The method of claim 18, wherein the disorders are selected from the group consisting of bowel disorders, ulcers, inflammatory bowel syndrome disorder, irritable bowel syndrome disorder, arrhythmia, and high blood pressure.

20. A method of treating psychiatric, neurological and neuroendocrine disorders in a mammal, the method comprising the steps of:

applying a focused ultrasound pulse (FUP) to a live neuronal circuit, where the applied FUP uses a low frequency to disrupt the neuronal circuits or a high frequency to activate the neuronal circuits;

monitoring a brain image from a brain imaging system during the application of the FUP;

administering a pharmaceutical medication to the mammal;

allowing the pharmaceutical medication to distribute to a target location in the brain of the mammal;

applying a second FUP to the target location in the mammal to alter the pharmaceutical medication at the target location; and

assessing a response to the pharmaceutical medication from the mammal with the brain image from the imaging system after the application of the second FUP.

21. The method of claim 20 further including monitoring the pharmaceutical medication in the mammal with the imaging system to determine when the pharmaceutical medication is distributed to the target location in the mammal.

22. The method of claim 20, wherein the focus of the FUP is about 2 or more centimeters into the brain from the exterior of the skull.

23. The method of claim 20, wherein the focus of the FUP is from about 2 cm to about 12 cm into the brain from the exterior of the skull.

24. The method of claim 20, wherein the frequency of the FUP is less than 300 Hz.

25. The method of claim 20, wherein the frequency of the FUP is from about 500 Hz to about 5 MHz.

26. The method of claim 20, wherein a diameter of the focus area of the FUP is about 0.5 mm.

27. The method ofclaim 20, further comprising the steps of:

adjusting a frequency and phase of the second FUP to change the focus of the second FUP; and

applying a third FUP to the target location.

28. The method of claim 20, further comprising the step of running a pre-timed computed tomography (CT) scan to determine bone density and structure of bone surrounding the brain.